| Compound | ACE-031 |
|---|---|
| Category | Myostatin inhibitor (Fc fusion) |
| Class | Growth Hormone and Growth Factors |
| Evidence tier | Clinical-stage |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
ACE-031 — a myostatin inhibitor (fc fusion) — sits in the "Clinical-stage" tier of this catalog. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
A recombinant fusion protein that acts as a myostatin decoy receptor, developed for muscular dystrophy. Clinical development was halted after safety findings.
Mechanism of Action
ACE-031 is an activin receptor type IIB extracellular domain fused to an antibody Fc; it sequesters myostatin and related ligands, removing the brake on muscle growth.
Research and Evidence
Phase 2 trials in Duchenne muscular dystrophy and healthy volunteers showed muscle-mass increases — but also adverse signals including nosebleeds, gum bleeding, and telangiectasias, ending development.
Safety and Side Effects
The discontinued program is a reminder that systemic myostatin blockade has real vascular effects. The compound has no approved use.
Frequently Asked Questions
What is the evidence tier of ACE-031?
ACE-031 is graded "Clinical-stage" on this site. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
Is ACE-031 an approved medicine?
No. Clinical-stage means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for ACE-031?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — registered ACE-031 studies. [source]
Evidence tier: Clinical-stage · Last reviewed: 2026-09-05 · Sources cited below.